OncoMatch

OncoMatch/Clinical Trials/NCT06732492

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

Is NCT06732492 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies RD13-02 cell infusion for nk t-cell lymphoma.

Phase 1RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT06732492Data as of May 2026

Treatment: RD13-02 cell infusionThis is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 Chimeric Antigen Receptor-T(CAR-T) therapy for patients with CD7-positive relapsed or refractory natural killer/T cell lymphoma, and to evaluate the pharmacokinetics of CD7 CAR-T in patients。

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Multiple Myeloma

Myelodysplastic Syndrome

Chronic Lymphocytic Leukemia

Biomarker criteria

Required: CD7 positive expression (positive)

CD7 positive expression

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: anticancer therapy

Exception: before CAR-T infusion

Subjects with some anticancer therapy before CAR-T infusion will be excluded.

Lab requirements

Blood counts

Bone marrow lymphoblasts ≥5% by morphologic evaluation at screening

Kidney function

Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min

Liver function

Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST) < 3×upper limit of normal, Total bilirubin < 1.5×upper limit of normal or ≤1.5mg/dl

Cardiac function

Left ventricular ejection fraction ≥ 50%

Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min, Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST) < 3×upper limit of normal, Total bilirubin < 1.5×upper limit of normal or ≤1.5mg/dl; Left ventricular ejection fraction ≥ 50%.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify